## **EXHIBIT A, PART 2**

**EXHIBIT 13** 

## What to include on an ICR Report

Provide the following details:

- All applicable dates: date of report, procedure, date you were first notified.
- Your contact information.
- Physician/Hospital Information (name, address, etc.
  - Patient Information (if available)
- How the device was used.
- Clear, concise event description (what happened before, during and after procedure).
- Product Information and Serial/Lot numbers that were involved in he event.
- fany information is not available or unknown, please indicated 'N/A" or "UNK" in the appropriate field the appropriate field






## Your Responsibility

Remember the clock starts ticking once you find o notify QA and forward ICR reports within two business days of becoming aware of complaintabout the event

information regarding all reports of alleged product To obtain and provide accurate and complete deficiencies and adverse patient events.

To request and obtain the actual device that was involved in the event for product evaluation.





## FOR REFERENCE ONLY INITIAL CONTACT REPORT

(Product Complaint Documentation)

	Date: (month/date/year)
QA-Assigned ICR Number:	RMA Number:
PMI employee or Sales Representative completing form:	- <b>-</b>
Hospital Involved:	Account #:
Address:	Telephone:
Person who encountered difficulty:	Title:
A. PATIENT INFORMATION:	to the Early Control of the Control
Age at the time of event: or Date of Birth:	Sex: Female Male
•	if unchecked, presumed No) \( \subseteq \text{No} \subseteq \text{Yes}
	The monte occur, presumed No) [1] No [1] 165
B. ADVERSE EVENT/PRODUCT PROBLEM:	
PROCEDURE: Date: Type:	and Indication:
*Date sales representative/PMI employee was first not	ified of event/problem:
Problem as described to you (please be specific):	*
•	Current patient status?
<u> </u>	
Did the difficulty result in any tissue damage or patient in	njury? (e.g. unanticipated tissue loss; unintended colostomy,
Did the difficulty result in any tissue damage or patient is resection or re-operation; unexpected/prolongation of hospitals.	
resection or re-operation; unexpected/prolongation of hosp	oitalization)
resection or re-operation; unexpected/prolongation of hosp	
resection or re-operation; unexpected/prolongation of hosp	oitalization)
<ul> <li>If applicable, what was done to correct this condition? (b)</li> <li>Relevant tests/laboratory data, including dates:</li> <li>Other relevant history, including pre-existing medical condition?</li> </ul>	pitalization) No Yes (explain; be specific)  pe specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction : Diabetes :
<ul> <li>• If applicable, what was done to correct this condition? (b</li> <li>• Relevant tests/laboratory data, including dates:</li> <li>• Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artheresch</li> </ul>	pitalization) No Yes (explain; be specific)  De specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy : Prior Radiation Therapy : Artheresc!     • General attitude of medical practitioner regarding the part.	pitalization) \[ \] No \[ \] Yes (explain; be specific)  Description of the specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction \[ \]; Diabetes \[ \]; erotic Cardiovascular Disease \[ \]; etc.?)
If applicable, what was done to correct this condition? (b     Relevant tests/laboratory data, including dates:     Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the patents.	pitalization) \[ \] No \[ \] Yes (explain; be specific)  Description of the specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction \[ \]; Diabetes \[ \]; erotic Cardiovascular Disease \[ \]; etc.?)
Relevant tests/laboratory data, including dates:     Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the path.  C. SUSPECT MEDICAL DEVICE:	pitalization) \[ \] No \[ \] Yes (explain; be specific)  Description of the specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction \[ \]; Diabetes \[ \]; erotic Cardiovascular Disease \[ \]; etc.?)
e If applicable, what was done to correct this condition? (be Relevant tests/laboratory data, including dates:  • Other relevant history, including pre-existing medical of Coagulopathy ☐; Prior Radiation Therapy ☐; Artheroscles General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE:  Product (s) code:	pitalization) \[ \] No \[ \] Yes (explain; be specific)  Description of the specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction \[ \]; Diabetes \[ \]; erotic Cardiovascular Disease \[ \]; etc.?)
■ If applicable, what was done to correct this condition? (b) ■ Relevant tests/laboratory data, including dates: ■ Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the path of C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):	pitalization) \[ \] No \[ \] Yes (explain; be specific)  Description of the specific e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction \[ \]; Diabetes \[ \]; erotic Cardiovascular Disease \[ \]; etc.?)
• If applicable, what was done to correct this condition? (b • Relevant tests/laboratory data, including dates: • Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescl • General attitude of medical practitioner regarding the pat  C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):	pitalization) No Yes (explain; be specific)  per specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy : Prior Radiation Therapy : Artherescle General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation.	pitalization) No Yes (explain; be specific)  Descriptions (e.g. cautery, sutured, applied another device, etc.)  Conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  Significant status?
e If applicable, what was done to correct this condition? (be Relevant tests/laboratory data, including dates:  • Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artheresel • General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation of the product (s) be sent back to PMI for evaluation of the product (s) product(s) be sent back to PMI for evaluation of the product (s) product(s) be sent back to PMI for evaluation of the product (s) product(s) be sent back to PMI for evaluation of the product (s) product(s)	pitalization) \[ \] No \[ \] Yes (explain; be specific)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)  The especific e.g. cautery, sutured, applied another device, etc.)
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the path of C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation? □ No □ Ye  Are other samples being sent for evaluation? □ No □ Ye	pitalization)  No Yes (explain; be specific)  per specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artheresele General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation of the procedure of	pitalization)  No Yes (explain; be specific)  per specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?
If applicable, what was done to correct this condition? (b     Relevant tests/laboratory data, including dates:     Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the path of C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation of the procedure of the relevant devices/product(s) involved in the procedure of the proc	pitalization)  No Yes (explain; be specific)  per specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?  cons/How many units had the reported defect:  ation No Yes  ss If yes, number of samples to be returned:  e (if any):
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy : Prior Radiation Therapy : Artherescle General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation of the procedure of t	pitalization)  No Yes (explain; be specific)  per specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?  cons/How many units had the reported defect:  ation No Yes  ss If yes, number of samples to be returned:  e (if any):
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy ; Prior Radiation Therapy ; Artherosol.     • General attitude of medical practitioner regarding the path C. SUSPECT MEDICAL DEVICE: Product (s) code: Description (s): Lot/Serial number (s): How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation in the procedure of the content of the procedure of the content of the sales representative or PMI employee of Occupation:	pitalization)  No Yes (explain; be specific)  be specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?  cons/How many units had the reported defect:  tation No Yes  ss If yes, number of samples to be returned:  e (if any):
• If applicable, what was done to correct this condition? (b     • Relevant tests/laboratory data, including dates:     • Other relevant history, including pre-existing medical of Coagulopathy □; Prior Radiation Therapy □; Artherescles General attitude of medical practitioner regarding the path of the code:  C. SUSPECT MEDICAL DEVICE:  Product (s) code:  Description (s):  Lot/Serial number (s):  How many surgically applied units did not meet expectation will the device(s)/product(s) be sent back to PMI for evaluation of the code of the relevant devices/product(s) involved in the procedure.	pitalization)  No Yes (explain; be specific)  be specific e.g. cautery, sutured, applied another device, etc.)  conditions (e.g. Hepatic/Renal Dysfunction ; Diabetes ; erotic Cardiovascular Disease ; etc.?)  tient status?  cons/How many units had the reported defect:  tation No Yes  ss If yes, number of samples to be returned:  the (if any):  Phone:

. )

VICTORIA



## Agenda

1.PMI Quality System

Vicki Simon - 261-84715-8156

2. Review of QSR's

Vicki Simon

Allyson Junod



the systems that a company roducts and services meel puts in place to assure its



## Men. Depar **О**О

The Quality Assurance Department provides to all interested parties the documented evidence provided by testing, trending, auditing, et that the quality systems are functioning properly. The documented evidence is

The Quality Assurance Department is not the conscience of the company



# perates in a Regulated Industi

Is an FDA registered Medical Device Manufacturer Adheres to the Quality System Regulation (QSR's)

13485:20 Is ISO 9001:2000 and ISO certified

5. Has a Quality Policy



## r Registrar, has been audited PMI is inspected by FDA, audited financial backers an undergoes internal self audits by potential

This also includes the Sales organization!



, PMI's electronic document documents that can be accessed through PMI Quality Documents are controlled MasterControl TM control system. System Administrator is Marissa Fleck if you are in need of assistance.



# PMI Quality Documents

. Quality Manual: 12-00001

2. Quality Policy: QP-00001

3. Management of Customer Complaints: SOP-00011

4. Medical Device Reporting: SOP-00037

-abeling (IFU's, Operator's Manual, Product labels MasterControl also has as controlled copies of al



Fower Wedical Interventions Continuous Flow of Innovation

## Overview

• The Law

· Compliance with the Law

Key Definitions

Adverse Event Reportir

Who to Contact



Requiations

FDA mandates the need for a formal complaint handling process (21 CFR 820) IN 2 DMUS

nvolve safety issues or actual adverse patient events (21 CFR 803) {Medical Device Reporting} A must be made aware of ANY complaints that

Medical Device GMP (21 CFR 820 subpart 198)

orocedures for receiving, reviewing and evaluating Each manufacturer shall maintain complaint files. Each manufacturer shall establish and maintain mplaints by a formally designated unit



## The Law

## FDA Regulations

Procedures shall ensure that:

All complaints are processed in a uniform and timely manner. Oral complaints are documented upon receipt

Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to the FDA Product Complaints and Adverse Event Reports are LEGAL requirements. Every PMI employee has a role



## By Complying with the Law. we:

- Maintain PMI's financial vitality.
- Continue the company growth.
- No late ICR report submissions = No late MDR submissions = No FDA Observations.

- Prevent loss of market share,
- Reduce market risks.
- Reduce legal liabilities.
- Provide Customer Satisfactior
   Responsiveness to customer.
- Drives Corrective Action
  - Propels product enhancement.



Somplaint: Any written, electronic or ora communication that alleges deficiencies related to the:

Identity

Quality

Durability

·Reliability

·Safety

• Effectiveness

•Performance

of any PMI product after it is released for distribut



Power Medical Interventions

## PMI's Return Policy

OVERSTER

isposable products may thin 60-days l'eac nase date DOXES OF a 20% rest osable assessed



## PMI's Return Policy


covered under the manufacturer's limited customer will be liable for any repairs not warranty. Equipment warranty is one (1) responsibility to maintain this equipment terms and conditions found in OPMA] year from the date of shipment. [Full n proper working condition and the Equipment – It is the customer's



## PMI's Return Policy

has a serial/pa assigned

held accountable for you You are responsible an system/produc



# 

notification of Return and obtai Call Customer Service with

(ICR) needs to be completed if a complaint (defaul case) within 24 hours Initial Contact Report n a clinical



# Procedure/RMAs

/Return of Product > Credit or Repair

- Packaging (replaced automatically when used Used product must be returned in Biohazard
- Package is be clearly marked "Used healthcare product"
- Repair cost may be involved
- Replacement or repaired product is sent to Sales Associate for delivery to customer



Power Medical interventions Continuous Flow of Innovation™

## **EXHIBIT 16**

## Esposito, Rita

From:

Sent:

Chase, Robert Monday, November 01, 2004 10:58 AM Tantiado, Myrick

To:

Çc:

Mintun, Keith; Esposito, Rita; Convery, Kevin 60 Day Performance review

Subject:

Myrick,

Please see the attached 60 Day performance review letter.

**Rob Chase** General Manager
Power Medical Interventions email: rchase@pmi2.com Ph: 415-793-5197



Tantiado Perf Review Ltr 1104....





November 1, 2004

To: Myrick Tantiado

From: Rob Chase

Subject: Sixty day performance review

Cc: Kevin Convery, Keith Mintun, Rita Esposito

Dear Myrick,

This letter is to inform you that your performance over the past two months (Sept-Oct, 2004) ranks you as one of the top performing Sales Associates for PMI. Thank you for taking a leadership position in contributing to the company's success.

Our goal is still an aggressive one and I'm sure that you will continue to raise your own performance standard and continue to increase your revenue production each month.

PMI and I will continue to support your selling efforts. Call on me when needed to assist with your action plans.

We all look forward to your strong start leading to continued territory successes. When you succeed, we all succeed.

Regards,

**Rob Chase** 

## **EXHIBIT 18**

EXHIBIT TOWN TOWN

Power Inchigan

The Ultimate Medical Technology "

Sales Representative of the V

| Power Medical

## **EXHIBIT 19**



2021 Cabot Boulevard Langhorne, PA 19047 Phone: 1-866-POWERMED Fax: 267-775-8122

March 24, 2006

Myrick Tantiado 233 Winding Way San Francisco, CA 94112

Dear Myrick:

Congratulations on your promotion to Regional Manager for the Bay Area territory, commencing on February 13, 2006. You will report to John Roache, Vice President of Sales.

You shall be paid on a salary basis at an annual rate of \$75,000, to be paid bi-weekly. In addition, you are eligible to participate in our monthly commission plan. The commission will be paid monthly at 5% commission on all regional sales generated from the previous month. The Company reserves the right to periodically reassess the commission percentage. As a member of the field sales selling organization you will also receive a monthly car allowance of \$600.00 to apply to car and insurance expenses.

As Regional Manager your responsibilities include but are not limited to:

- 1. Exceeding quota objectives that are in alignment with the PMI Mission, Purpose and Core Values.
- 2. Developing a business plan with metrics that are aligned with your Region's goals.
- 3. Hiring qualified candidates to fill open Sales Associate or Senior Sales Associate positions.
- 4. Coaching and managing your staff's performance.

Further, it is our intention to recommend to the Board of Directors that you be granted a stock option grant in the amount of 5,000 shares to vest in accordance with the 2004 Stock Option Plan.

Your employment at all times will be at will, meaning you are not being offered employment for a definite period and that either you or PMI may terminate the employment relationship at any time for any reason.

Thank you for your continued efforts and best of luck in your new position as Regional Manager.

Sincerely,

Accepted by:

Rita Esposito Director, Human Resources

Myrick Tantiado

Date \_\_\_\_

EXHIBIT Tanfrado 20 4-10-08

MT 216

## **EXHIBIT 20**



2021 Cabot Boulevard Langhorne, PA 19047 Phone: 1-866-POWERMED Fax: 267-775-8122

March 24, 2006

Myrick Tantiado 233 Winding Way San Francisco, CA 94112

Dear Myrick:

Congratulations on your promotion to Regional Manager for the Bay Area territory, commencing on February 13, 2006. You will report to John Roache, Vice President of Sales.

You shall be paid on a salary basis at an annual rate of \$75,000, to be paid bi-weekly. In addition, you are eligible to participate in our monthly commission plan. The commission will be paid monthly at 5% commission on all regional sales generated from the previous month. The Company reserves the right to periodically reassess the commission percentage. As a member of the field sales selling organization you will also receive a monthly car allowance of \$600.00 to apply to car and insurance expenses.

As Regional Manager your responsibilities include but are not limited to:

- Exceeding quota objectives that are in alignment with the PMI Mission, Purpose and Core Values.
- 2. Developing a business plan with metrics that are aligned with your Region's goals.
- 3. Hiring qualified candidates to fill open Sales Associate or Senior Sales Associate positions.
- 4. Coaching and managing your staff's performance.

Further, it is our intention to recommend to the Board of Directors that you be granted a stock option grant in the amount of 5,000 shares to vest in accordance with the 2004 Stock Option Plan.

Your employment at all times will be at will, meaning you are not being offered employment for a definite period and that either you or PMI may terminate the employment relationship at any time for any reason.

Thank you for your continued efforts and best of luck in your new position as Regional Manager.

Sincerely,

Accepted by:

Rita Esposito Director, Human Resources

Myrick Tantiado

Date

EXHIBIT Tantiado 20 4-10-08

MT 216

From: Chase, Robert

Sent: Saturday, June 17, 2006 11:19 AM

To: Tantiado, Myrick

Subject: Sales for the month

Myrick,

I hope all is well. Just wanted to make sure you get to 20K for the month. Marin should bring 5k then you need another 15K from the other targets we discussed. It's critically important that you get to 20k for the month as we discussed on the phone. I will call you when I get back in town but have a great next week.

Rob.



Page 38 of 49



2021 Cabot Boulevard Langhorne, PA 19047 Phone: 1-866-POWERMED Fax: 267-775-8197

July 10, 2006

1

Mr. Myrick Tantiado 233 Winding Way San Francisco, C 94112

## PERSONAL & CONFIDENTIAL

### Dear Myrick:

Your employment is being terminated effective today, July 10, 2006. You will be paid your base salary and car allowance through July 10, 2006. Should you accept the terms of this letter, the company agrees to pay you a severance pay which will include ten (10) days base pay in lieu of notice. Any commissions earned during the months of June and July will also be paid to you on regularly scheduled commission pay dates. PMI will pay you for any accrued, unused vacation days. Once all outstanding company property has been received in Langhorne, PMI will issue any payments that are due.

Your health and dental insurance will end on July 30, 2006. A COBRA letter reviewing specific details of your medical and dental insurance benefit continuation will be mailed to your home by in the next couple of weeks. All other benefits will end on July 10, 2006.

Please return all Company property as outlined in the forthcoming letter no later than July 20, 2006. Please take the equipment to a Mailboxes Etc. store near you and have them properly package and ship the equipment back to PMI at 2021 Cabot Blvd. West, Langhorne, PA 19047. Please include the assigned RMA number when returning your equipment.

You are reminded of the Non-disclosure policy contained in Section 112 of the employee handbook, which you acknowledged receipt of upon hire. You are also reminded of the confidentiality agreement, which you signed when you joined the company. This agreement remains in effect and as such, you are not at liberty to divulge any company proprietary or confidential information to anyone outside Power Medical Interventions. You must make every effort to maintain and protect the reputation of Power Medical Interventions and that of their products, directors, officers and employees. You further agree that you will not disparage PMI or their products, directors, officers and employees or engage in any activities that reasonably could be anticipated to harm their reputation, operations, or relationships with current or prospective customers, suppliers or employees.

EXHIBIT
Tantiads
24
4-10-08

I wish to take this opportunity to express our appreciation for helping to move the company forward and wish you every success in your future endeavors.

Should you have any questions or concerns please do not hesitate to contact me at 267-775-8119.

Please sign and fax this letter back to me at 267-775-8197.

Very truly yours,	Received by:		
RC	•	•	
Peta Espoito		_	
Rita Espositó	•	Date:	·
Director Human Percurces	Myrick Tentiado		

From: Sent:

Tantiado, Myrick

To: Cc: Subject: Wednesday, May 17, 2006 1:48 PM

Diehlman, Robin

Singh, Noef, Leonard, Brian D. RE: SurgAssist Product Return

Importance:

Robin.

Thank you for your email. I will contact Noel to help process the Surgassist product

Sincerely,

Myrick Tantiado Power Medical Interventions (415) 596-3405 Cell (415) 349-8444 Fax

-Criginal Message----From: Diehlman, Robic [mailto:Robin.Diehlman@ucsfmedctr.org]
Sent: Fri 5/12/2006 8:43 PM To: Tantiado, Myrick Cc: Singh, Noel; Leonard, Brian D. Subject: Surgassist Product Return

Hi Myrick,

Noel has made multiple attempts to coordinate product information with you so that we can prepare our SurgAssist product return.

Could you please coordinate this with him at your earliest convenience?

Thank you, Robin

Robin Diehlman OR Materials 415-353-1884 v.m. 415-353-8559 fax robin.diehlman@ucsfmedctr.org

UCSF Medical Center 505 Parnassus Avenue, M61F, Box 0200 San Erancisco, CA 94143

This email is intended only for the person or entity to which it is addressed, and may contain information that is privileged confidential, or otherwise protected from disclosure. Dissemination, distribution, or copying of the smail or the information herein by anyone other than the intended recipient is prohibited. If you have received this email in error, please notify the sender by reply email, and destroy the original message and





Filed 07/25/2008

ONS® 2021 Cabot Boulevard West Langhome, PA 19047 Ph; 1-866-POWERMED Fax: 267-775-8122 www.pmiZ.com

August 18, 2006

Mr. Myrick Tantiado 233 Winding Way San Francisco, CA 94112

Dear Myrick:

I am writing concerning the issue of product returns (and related refunds) from one of your accounts, University California - San Francisco. As you are aware, it is Power Medical's policy that any sales commissions paid to its sales representatives are subject to offset if those same products are subsequently returned by customers. In this case, UCSF has returned merchandise for which a total credit of \$13,789.00 has been issued by PMI. This would equate to \$1,525.59 in forfeited commission, such amount is to be withheld from your final expense reimbursement payment. The remaining expense reimbursement will be paid to you in the amount of \$2,937.68, through PMI's next scheduled payroll on August 25, 2006.

You have claimed that since these actual goods were not received by PMI until after your departure that somehow you are exempt from the policy. In fact, discussions between you and this customer regarding the return of product began long before you left PMP's employ as the attached email correspondence between you and Robin Diehlman indicates. I hope this answers any questions you may have. Should you have any questions concerning the attached, please feel free to call.

Sincerely,

Rita Esposito, PHR

Director, Human Resources

Page 46 of 49

From: Sent

Tantiado, Myrick

To:

Wednesday, May 17, 2006 1:48 PM

Cc: Subject: Diehlman, Robin

Singh, Noel, Leonard, Brian O. RE: SurgAssist Product Return

Importance:

High

Robin.

Thank you for your email. I will contact Noel to help process the SurgAssist product

Sincerely,

Myrick Tantiado

Power Medical Interventions (415) 596-3405 Cell (415) 349-8444 Fax

From: Diehlman, Robin [mailto:Robin.Diehlman@ucsfmedctr.org]
Sent: Fri 5/12/2006 8:43 PM To: Tantiado, Myrick Cc: Singh, Noel; Leonard, Brian D. Subject: SurgAssist Product Return

Hi Myrick,

Noel has made multiple attempts to coordinate product information with you so that we can prepare our SurgAssist product return.

Could you please coordinate this with him at your earliest convenience?

Thank you, Robin

Robin Diehlman OR Materials 415-353-1884 v.m. 415-353-8559 fax robin.diehlman@ucsfmedctr.org

UCSF Medical Center 505 Parmassus Avenue, H61F, Box 0200 San Francisco, CA 94143

This email is intended only for the person or entity to which it is addressed, and may contain information that is privileged confidential, or otherwise protected from disclosure. Dissemination, distribution, or copying of the email or the information herein by anyone other than the intended recipient is prohibited. If you have received this email in error, please notify the sender by reply email, and destroy the original message and all copies.





# SURGASSIST COMPUTER POWERED STAPLING SYSTEM

Product	Description	OTY RETURNED
Surg 200	SurgAssist Computerized/Robotic Surgical System	
	Includes:  (1) Single Driver Power Console (2) FlexShaft II (15mm Flexible Steering Shafts) (2) Remote Control Units (1) Mobile Cart (1) Program Memory Card (1) Manual Release for FlexShaft II, 15mm (1) Operator Manual (1) Power Cord	1

# POWER MEDICAL RETURNS

Γ	- 1		_,_		\				<del></del>			 	 , C	,	 	 
	S EA SENT TO	1 BX SENT TO	MOFFILL													
P.O.	960742	965783	964931	930601	930601	930601	930601	930601	109066	930601	930601					
QTY	0 EA	0 BX	2 BX	1 BX	1BX+5EA	1 BX	1 BX	11 EA	2 BX	10 EA	11 EA					
PMM	12568	12570	12535	12536	12537	12538	12528	12531	12526	12530	12533					
DESCRIPTION	RT ANGLE LINEAR CUTTER 30MM RALC30	RT ANGLE LINEAR CUTTER VAS 30MM	RT ANGLE LINEAR CUTTER 45MM RALC45	CIRCULAR STAPLER 25MM CS25	CIRCULAR STAPLER 29MM CS29	CIRCULAR STAPLER 33MM CS33-	STRAIGHT CUTTER 55MM SLC55G	RELOADS 55MM SLCR55G	STRAIGHT CUTTER 5SMM SLC55B	RELOADS 55MM SLCR55B	POWER CUTTER RELOADS 75MM PLCR75B					

7-26-06 SA DLU RECALL.HR UCSF 111

Page1 of 1

NOTE: Unless otherwise noted; if Unit of Measure (UOM) = EA, the product is out of the original product box, but still in it's original sterile packaging. If UOM = BX, the product is in it's original product box and in it's original product box and

MT. ZION	-		•							
endor Çati S297	Veridor Call* Description.  Veridor Call* Description.  Particle Call* C	UCSF.PMM#. QTY	Y. UOM	UCSF PO Value		Ext. Value	NOTES		KWW Kilcredit	REDIT
529 533435554	STAPLER CIRCULAR (EVAL) 29MM CS29	12537	5 EA	964937	\$405.00	\$2,025.00	A A STUDIO GO SES ZOON OF STANKE STAN			00000
1055G	SPEAK STAND STAND STRAIGHT IN SAND STAND SEAM OF SEAM OF SEASONS SEAM OF SEAM	2528	(B)	10900			Retrinolic Retrinolics 20)			00000
SIGS58		(25267.11.15.15)	11 EA	930601	\$135.00 \$2.0/@005	\$1,485.00	REMINERAL SAME			
PLCR75B	RELOAD STRAIGHT LINEAR CUTTER 55MM BLU SLCR55B RELOAD STRAIGHT LINEAR CUTTER 75MM BLU PLCR75B	12530 12533	5 E B B	930601 930601	\$135.00 \$180.00	\$1,350.00 \$1,980.00	\$1,350.00 \$1,980.00			0.00
		Ď	FAL RETURN	TOTAL RETURN VALUE FOR MT. ZION:	IT. ZION:	\$24,076.00		•	\$17,23	17,23
MOFFITT LONG Vendor Cat# D	MOFFITT LONG Vendor Cat# Description	UCSF PMM# OTY	200	2 (8 18 )				Less 20% Re-Stocking Fee Credit Due	:	\$3,447 \$13,788.00
		y		OCST PO Valde		Ext. Value	NOTES		RIMA	15%
RALC30 CS21 CS26	CUTTER LINEAR (EVAL) 30MM RIGHT ANGLE RALC30 STAPLER CIRCULAR (EVAL) 21MM CS21 STAPLER CIRCULAR (FVAL) 25MM CS23	12568 non-cat	ង <b>ង</b> ៖	960742 971342	\$326,33 \$405,00	\$978.99 \$1,215.00	THIS PO IS A MT. ZION PO BEGAUSE IT IS MOST 8878.99 LIKELY THESE ARE FROM MT. ZION STOCK 1.215.00	SAUSE IT IS MOST ZION STOCK	Samuel So	\$2,068.35
SLCR55G SLC55B	RELOAD STRAIGHT LINEAR CUTTER SSMM GRN SLCRSSG CUTTER LINEAR (EVAL) DLU STRAIGHT SSMM BLU SLCSSB	12531 12531 12526	2		\$405.00 \$135.00 \$402.00	\$3,645,00 \$1,485.00			Myricleso	yrickowes Pm
SLCR55B SLCR55B PCS21	RELOAD STRAIGHT LINEAR CUTTER 56MM BLU SLCR55B RELOAD STRAIGHT LINEAR CUTTER 55MM BLU SLCR55B STAPLER CIRCULAR 21MM PCS21	12530 12530 12534	2 2 2 2 2 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3	1002770 goneba 929413	\$135.00 \$135.00 \$960.00	\$1,620.00 \$1,350.00 \$1,920.00				
P.LC75	CUTTER LINEAR (EVAL) 75MM REPOSABLE 20 USE PLC75	12532 TOTAL RE	2 EA TURN VALUE	2 EA 929413 \$1,350,00 TOTAL RETURN VALUE FOR MOFFITT LONG:	1,350,00 r <b>Long:</b>		ITEM IS OUT OF VENDOR'S ORIGINAL STERILE PACKAGING AND IS IN UOSF PEEL PACKS INSTEAD	KIGINAL STERILE FEL PACKS		
			RETURN VAL	TOTAL RETURN VALUE FOR BOTH SITES:	I SITES:	\$39,793.99				
	证据的原则是是 * ACTUAL PURCHASE PO WOULD NEED TO BE CONFIRMED BY LOT#	LOT#								
	- 2668,35 Myrick ou	ocles Pmz			ę	•				C
	542,00 Jun "earne.	"Earney" Commissions			D S	Gedui	of from Mye	Z		)
	(1,586.35) (0,	Comment.			i	F	that his	•		
		1				M	dered report	$\forall$		
	ユー ぐつよのこび	Ц					_			
	l <sub>t</sub>	1 1 20 00					Steplan	١		
	•	T. C. t.					Wrt 18			